Joe Glass, PhD, MSW, is an associate investigator at Kaiser Permanente Washington Health Research Institute (KPWHRI). Before joining KPWHRI in July 2016, he was an assistant professor at the University of Wisconsin–Madison School of Social Work.
Dr. Glass’ research seeks to understand how effective health care interventions for unhealthy alcohol and drug use can reach more people. His research seeks to answer these questions:
Much of Dr. Glass’ recent work, funded by the National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, and Kaiser Permanente, is studying approaches for routinely using smartphone and web-based treatments for unhealthy alcohol and drug use in health care. After receiving an MSW from the University of Michigan, Dr. Glass spent three years as a social worker at the Veterans Affairs Ann Arbor Healthcare System. As a licensed clinical social worker in a large mental health clinic, he developed expertise in social work case management and evidence-based treatments for anxiety, depression, and substance use disorders. Much of his research is driven by his clinical experiences, considering the many people struggling with both mental health difficulties and unhealthy substance use who have yet to receive addiction treatment.
Dr. Glass is an affiliate assistant professor of health services and of psychiatry and behavioral sciences, at the University of Washington.
Brown R, Deyo B, Riley C, Quanbeck A, Glass JE, Turpin R, Hetzel S, Nicholas C, Cruz M, Agarwal S. Screening in Trauma for Opioid Misuse Prevention (STOMP): study protocol for the development of an opioid risk screening tool for victims of injury. Addict Sci Clin Pract. 2017;12(1):28. doi: 10.1186/s13722-017-0097-6. PubMed
Williams EC, Gupta S, Rubinsky AD, Glass JE, Jones-Webb R, Bensley KM, Harris AHS. Variation in receipt of pharmacotherapy for alcohol use disorders across racial/ethnic groups: A national study in the U.S. Veterans Health Administration. Drug Alcohol Depend. 2017 Sep 1;178:527-533. doi: 10.1016/j.drugalcdep.2017.06.011. Epub 2017 Jul 11. PubMed
Lehavot K, Blosnich JR, Glass JE, Williams EC. Alcohol use and receipt of alcohol screening and brief intervention in a representative sample of sexual minority and heterosexual adults receiving health care. Drug Alcohol Depend. 2017 Oct 1;179:240-246. doi: 10.1016/j.drugalcdep.2017.07.003. Epub 2017 Aug 2. PubMed
Busch AC, Shivaram M, Glass JE, Hetzel S, Gugani SP, Gassman M, Krahn D, Deyo B, Brown RT. Pre-discharge injectable vs. oral naltrexone to improve post-discharge treatment engagement among hospitalized veterans with alcohol use disorder: a pilot proof-of-concept study. Alcohol Clin Exp Res. 2017 Jul;41(7):1352-1360. doi: 10.1111/acer.13410. Epub 2017 Jun 12. PubMed
Busch AC, Denduluri M, Glass J, Hetzel S, Gugnani SP, Gassman M, Krahn D, Deyo B, Brown R. Predischarge injectable versus oral naltrexone to improve postdischarge treatment engagement among hospitalized veterans with alcohol use disorder: a randomized pilot proof-of-concept study. Alcohol Clin Exp Res. 2017 Jul;41(7):1352-1360. doi: 10.1111/acer.13410. Epub 2017 Jun 12. PubMed
Amy Lee describes how the LHS Program is helping KP Washington track and improve treatment for opioid use disorder.
Drs. Lapham and Bradley find frequency of cannabis use can be tied to other behavioral health patterns and needs.
Health Affairs blog, Mar 11, 2020